The pathway to establishing and implementing opioid agonist therapy (OAT) for people who inject drugs in Nairobi, Kenya.

Authors

Emily Koech, Christopher Welsh, Mercy Karanja, Jebet Boit, Rebecca Wangusi, Patrick Awuor, Oscar Munyao, Tina Masai, Sam Wafula, Caroline Ngunu, Obwiri Kenyatta, Immaculate Mutisya, Jonathan Mwangi, Beatrice Gichuhi, Ansley Lyn, Kristen Stafford, Taylor Lascko, Geoffrey Ndichu, Caroline Ng'eno

Published in

Frontiers in public health. Volume 14. Pages 1717635. Epub Aug 03, 2026.

Abstract

Sub-Saharan Africa (SSA) is experiencing a burgeoning population of people who inject heroin. This has created an urgent need for the scale-up of comprehensive harm reduction services including medication for opioid use disorders. The rise in illicit drug use threatens the gains made in the fight against HIV in this high HIV burden region. People who inject drugs (PWID) have an increased risk of HIV acquisition and transmission due to factors such as needle sharing and engaging in high-risk sexual behaviors. Estimates show that PWID have a prevalence of HIV of 18.7%-nearly four times the prevalence in the general population in Kenya. To address this, Kenya adopted the comprehensive harm reduction package of services for PWIDs and in 2013, began preparation for the provision of Opioid Agonist Therapy (OAT) with the first clinic opening in 2014 at Mathari National Teaching and Referral Hospital (MNTRH). This paper describes the process and collaborative steps taken in establishing the OAT program in Kenya. It shares implementation achievements and lessons learned. Since the inception of OAT services in Mathari and Ngara clinics in Nairobi, over 80 healthcare providers were trained on the provision of OAT services between 2014 and 2023, and 3,354 individuals were initiated on OAT. The OAT program has expanded to include mobile OAT dispensing and satellite dispensing clinics, and in future, may include the use of take-home doses of Methadone and Buprenorphine and provide injectable long-acting Buprenorphine for increased uptake and continuity in treatment.

PMID:
42609332
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.